Specialty Pharmacy Trends and Technology at Asembia AXS25

The Asembia AXS25 Specialty Summit has been a place to bring stakeholders together to look at trends, consider how new technology can be used, and change the conversation about health care delivery for the benefit of patients.

The following individuals provided their insights into what they find most important about Asembia:

• Joe DePinto, head of cell, gene, and advanced therapies, McKesson
• Kathi Henson, MBA, senior vice president of patient services, nursing, and quality at Orsini
• Natalie Bedford, senior vice president, US pharmaceutical distribution services, McKesson

Transcript has been lightly edited for clarity; captions are auto-generated.

Transcript

What do you look forward to the most or find the most interesting at Asembia?

DePinto: Asembia is always a meeting I look forward to going to. One, to meet so many of my colleagues in the market access space, but in specialty pharmacy, it's becoming such a critical component of care delivery, and how do we look at, what are those trends in the space, what are some of the technology that can be used to facilitate treatment, and how do we make sure there's a more seamless delivery of care?

[There are] always great topics for me to sort of think about gathering great information from experts in the space, and Asembia never lets you down when it comes to that kind of information.

Henson: I am always super interested to see what other technological advancements there are, right? There's lots of interesting things, lots of software platforms, [and] lots of new adherence tools that are coming out that could really benefit patients. A lot of them are really interesting, but then, how do we take those and actually turn them into something that's real and that is useful for patients? Always lots of interesting conversations and looking forward to hearing what's happening.

Bedford: I think one of the things I'm saying I'm not only excited about, but I'm hopeful for, is we come to these conferences, we've all got our agendas on our business of today and maybe business in the next 12 to 18 months. And often—I'm not putting any of us in any segment into a bucket—I think all this can be noted for thinking about it just from our lens. And I think what I'm really excited to see is, let's have conversations that we're having collectively, because all of the challenges we're facing in this health care ecosystem, they impact more than just 1 segment.

How can we start changing the conversation on how do we think ahead, plan ahead, and start to define and design mutual solutions and capabilities that can mitigate the risk and impact to patients. Because at the end of the day, that's why we're all in this business, is because we want to make sure that we're bringing great, new, innovative medicines that can improve the quality of life or ultimately the outcomes for patients. If we don't work together to find solutions, none of us are going to be able successful in doing so.